Zeist, Netherlands

Jan Van De Winkel

This inventor holds 45 USPTO granted patents and 44 published patent applications, plus 15 CIPO patents and 34 EPO patents, primarily in Monoclonal Antibodies. Top assignees: Genmab A+s, Hoffmann-La Roche Inc., Roche Palo Alto LLC. Active years: 2008-2024.

USPTO Granted Patents = 45 

% Patents Active = 86.7

 

 

Average Co-Inventor Count = 8.4

ph-index = 14

Forward Citations = 639(Granted Patents)


Location History:

  • Zeist, NL (2008 - 2022)
  • Utrecht, NL (2015 - 2024)

Company Filing History:


Years Active: 2008-2024

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Monoclonal Antibodies
Bispecific Antibodies
Heterodimeric Antibodies
IgG4 Antibodies
Antibody Variants
Cancer Treatment
Human Antibodies
Anti-P-Selectin Antibodies
CD38 Antibodies
HER2 Antibodies
CD32b Antibodies
Drug Conjugates
45 patents (USPTO):Explore Patents

Title: Jan Van De Winkel - Innovative Inventor from Zeist, NL

Introduction: Jan Van De Winkel is a renowned inventor hailing from Zeist, Netherlands, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Jan Van De Winkel holds several patents in the areas of biotechnology, medical devices, and sustainable energy solutions, showcasing his diverse range of expertise and creativity.

Career Highlights: With a career spanning over two decades, Jan Van De Winkel has worked with leading research institutions and companies, spearheading projects that have revolutionized industries and improved the quality of life for many.

Collaborations: Throughout his career, Jan Van De Winkel has collaborated with top universities, multinational companies, and talented individuals, fostering a culture of innovation and excellence in all his endeavors.

Conclusion: Jan Van De Winkel's passion for innovation, coupled with his relentless drive to push boundaries, has solidified his reputation as a visionary inventor in the global tech community.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…